Osborne Clarke advises Endeavour Vision on its investment in Lumeon as part of a $30M funding round

Written on 11 August 2020

International legal practice Osborne Clarke has advised Endeavour Vision on its investment in Lumeon, a leader in care pathway orchestration. The investment is part of Lumeon’s $30M Series D investment round.

The investment will enable the company to extend the reach of its Care Pathway Management (CPM) platform, which helps healthcare providers automate their patient care coordination to improve care quality, deliver better outcomes and reduce costs.

Endeavour Vision is a leading private equity firm investing in growth-stage medtech and digital health companies. The round was co-led by Endeavour Vision and Optum Ventures with participation from current investors LSP, MTIP, IPF Partners, Gilde, and Amadeus Capital Partners.

Lumeon’s CPM platform uses real-time data to dynamically guide patients and care teams along their care journeys. By automating, orchestrating and virtualizing care delivery across care settings, Lumeon’s solutions allow health systems to operate with predictability and efficiency, delivering optimal care to each patient while substantially lowering costs for healthcare providers.

Partner Matthew Edwards, Senior Associate Jonathan Falconer and Associate Krish Mistry advised Endeavour Vision.

Osborne Clarke has a market-leading international venture capital practice and is widely recognised as a leading European law firm for companies operating in the life science and healthcare sector team. Its sector team has a strong track record of providing highly sophisticated advice to investors and digital health clients on cutting-edge issues, across multiple service lines. They work with blue chip venture capital firms, the biggest pharma, medical devices, medtech and digital health companies in the market.

Connect with one of our experts